NEW YORK, April 19 (GenomeWeb News) - Digene will market and distribute cystic fibrosis screening products made by Asuragen, the newly formed molecular diagnostic company spun out of Ambion, the partners said today.
Terms of the exclusive, worldwide deal call for Digene to make an up-front payment to Asuragen, and to make additional payments based on regulatory milestones.
Asuragen will also develop its next-generation CF test, Signature CF Expand, which will broaden the mutation panel to include ethnic-specific mutations that can be adapted for use in carrier screening and may find additional utility for neonatal and newborn testing. Digene will also distribute this product exclusively and worldwide.
In addition, Digene will have the first right of refusal on future genetic test products developed by Asuragen. The Signature products use the Luminex xMAP technology.
Asuragen was formed after Applied Biosystems acquired Ambion's RNA business in March.